Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure
Abstract Background Heart failure (HF) is a major cardiovascular complication of type 2 diabetes mellitus (T2DM). Sodium–glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) both improve cardiovascular outcomes, but their comparative roles in HF and t...
Wedi'i Gadw mewn:
| Prif Awduron: | , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2026-07-01
|
| Cyfres: | Cardiovascular Diabetology. Endocrinology Reports |
| Pynciau: | |
| Mynediad Ar-lein: | https://doi.org/10.1186/s40842-026-00319-y |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|